ICH = 2 Years after last approval based on study [Regulatives / Guidelines]

posted by Ohlbe – France, 2020-09-01 13:03 (1355 d 02:55 ago) – Posting: # 21906
Views: 2,106

Dear Brus,

❝ 2 Years for ICH? Where did you find that?


In ICH E6 (GCP), § 4.9.5:

Essential documents should be retained until at least 2-years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or at least 2-years have elapsed since the formal discontinuation of clinical development of the investigational product. These documents should be retained for a longer period however if required by the applicable regulatory requirements or by an agreement with the sponsor.

Cave: not 2 years after the end of the study, but 2 years after the last approval based on that study.

Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
23,029 posts in 4,834 threads, 1,641 registered users;
29 visitors (0 registered, 29 guests [including 5 identified bots]).
Forum time: 15:58 CEST (Europe/Vienna)

The most erroneous stories are those we think we know best–
and therefore never scrutinize or question.    Stephen Jay Gould

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5